Overview
In our study, changes in vastus lateralis muscle oxygenation will be evaluated with the Moxy device, a functional infrared oxygen measurement device, during the inspiratory muscle fatigue protocol in COPD cases and the healthy control group.
Eligibility
Inclusion Criteria:
- Having a diagnosis of Stage 2-3 COPD according to the following clinical diagnostic criteria according to the American Thoracic and European Respiratory Societies (ATS-ERS).
- Having been using the same medications for the last 4 weeks
Exclusion Criteria:
- Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and requiring high-flow oxygen therapy (˃ 3-4 L\min).
- Presence of any vascular problem that may affect lower extremity muscle oxygenation
- Presence of another respiratory system disease other than COPD
- Patients who have had an acute COPD exacerbation in the last 4 weeks
- Patients experiencing COPD exacerbations during the study protocol
- Presence of fatty tissue or scar tissue at the measurement points, which may impair the measurement quality.
- Have already participated in another clinical trial within the last 30 days that may affect the results of the study.
Inclusion Criteria for Healthy Cases
- Being over 18 years of age
- Not having any diagnosed chronic disease
- Not being a smoker